Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed a minor adjustment to its share capital following an on-market buyback executed on 14 October 2026.
The company repurchased 80,000 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 3.36 to HKD 3.40, for a volume-weighted consideration of HKD 270,900.
Key post-transaction metrics:
• Issued shares (excluding treasury stock) declined by 0.0018% to 4.45 billion. • Treasury shares increased to 67.52 million, up from 67.44 million. • Total issued shares remain unchanged at 4.52 billion, as the repurchased shares are held in treasury and have not been cancelled.
Repurchase capacity and mandate:
• The current buyback falls under the mandate approved on 29 May 2026, which authorises the repurchase of up to 446.46 million shares. • Cumulative buybacks under this mandate now stand at 10.19 million shares, representing 2.28% of the issued share capital on the mandate date. • In line with listing rules, Weigao Group is subject to a moratorium on new share issues or treasury share disposals until 14 November 2026.
The company confirmed all regulatory requirements and board authorisations were met for the transaction.
Comments